Format

Send to

Choose Destination
Clin Invest Med. 2009 Dec 1;32(6):E315.

Prognostic value of CRM1 in pancreas cancer.

Author information

1
Department of Oncology, Affiliated People's 1st Hospital, Shanghai Jiaotong University, Shanghai, PR China 200085.

Abstract

PURPOSE:

Pancreatic cancer is a highly aggressive malignant tumour with poor prognosis. The median survival is only 6 months. This study investigated the prognostic value of nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 (CRM1) expression in pancreas cancer.

METHODS:

CRM1 expression was detected, by Western blot, in pancreatic tissue from 69 cancer patients and 10 normal subjects.

RESULTS:

CRM1 showed increased expression in pancreatic cancer tissue (P = 0.007). The high expression of CRM1 was associated with increased serum levels of CEA (P = 0.002) and CA19-9 (P = 0.005). There was an association between CRM1 expression and tumour size (P = 0.01), lymphadenopathy (P = 0.004) and liver metastasis (P = 0.003). High CRM1 expression was not correlated with the other clinicopathological parameters. High CRM1 expression was a prognostic indicator for progression-free survival (PFS) (P = 0.006) as well as overall survival (OS) (P = 0.001). Expression of CRM1 was an independent prognostic parameter for poorer PFS and OS (95% CI, 1.27-5.39).

CONCLUSIONS:

CRM1 expression demonstrated prognostic value in pancreatic cancer. Prospective studies are required to determine the prognostic role of high expression of CRM1 in pancreatic cancer.

PMID:
20003838
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center